Eyenovia (NASDAQ:EYEN) released its quarterly earnings data on Monday. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.03, Bloomberg Earnings reports.
Shares of EYEN opened at $3.34 on Wednesday. The company has a market cap of $55.24 million, a P/E ratio of -1.84 and a beta of 1.11. Eyenovia has a one year low of $2.40 and a one year high of $6.98. The stock has a fifty day moving average price of $3.47.
Several research analysts recently commented on EYEN shares. Oppenheimer started coverage on shares of Eyenovia in a report on Wednesday, April 24th. They issued an “outperform” rating and a $9.00 target price on the stock. HC Wainwright set a $14.00 target price on shares of Eyenovia and gave the stock a “buy” rating in a report on Wednesday, June 5th. Zacks Investment Research upgraded shares of Eyenovia from a “sell” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, ValuEngine upgraded shares of Eyenovia from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
A hedge fund recently bought a new stake in Eyenovia stock. Bank of New York Mellon Corp acquired a new position in shares of Eyenovia Inc (NASDAQ:EYEN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,529 shares of the company’s stock, valued at approximately $36,000. Bank of New York Mellon Corp owned 0.11% of Eyenovia as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 7.88% of the company’s stock.
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Further Reading: What are the disadvantages of after-hours trading?
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.